JP2019521116A - 神経炎症及び神経変性を管理するための方法及び組成物 - Google Patents

神経炎症及び神経変性を管理するための方法及び組成物 Download PDF

Info

Publication number
JP2019521116A
JP2019521116A JP2018564826A JP2018564826A JP2019521116A JP 2019521116 A JP2019521116 A JP 2019521116A JP 2018564826 A JP2018564826 A JP 2018564826A JP 2018564826 A JP2018564826 A JP 2018564826A JP 2019521116 A JP2019521116 A JP 2019521116A
Authority
JP
Japan
Prior art keywords
cells
inhibitor
sirtuin
tyrosine kinase
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018564826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521116A5 (enExample
Inventor
サイエド、タスリマリフ
マンジターヤ、ラヴィ
クマール、ムルマーラ ラヴィ
クマール、ムルマーラ ラヴィ
サンティ ナテサン、サレシュ
サンティ ナテサン、サレシュ
パンデュランジ、ジャンハヴィ
ケイ チャヴァルマネ、アラヴィンダ
ケイ チャヴァルマネ、アラヴィンダ
ライ、シャシャンク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS(C−CAMP)
Original Assignee
CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS(C−CAMP)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS(C−CAMP) filed Critical CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS(C−CAMP)
Publication of JP2019521116A publication Critical patent/JP2019521116A/ja
Publication of JP2019521116A5 publication Critical patent/JP2019521116A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018564826A 2016-06-07 2017-06-07 神経炎症及び神経変性を管理するための方法及び組成物 Pending JP2019521116A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201641019577 2016-06-07
IN201641019577 2016-06-07
PCT/IB2017/053362 WO2017212420A1 (en) 2016-06-07 2017-06-07 Methods and compositions for managing neuroinflammation and neurodegeneration

Publications (2)

Publication Number Publication Date
JP2019521116A true JP2019521116A (ja) 2019-07-25
JP2019521116A5 JP2019521116A5 (enExample) 2020-07-27

Family

ID=60577634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564826A Pending JP2019521116A (ja) 2016-06-07 2017-06-07 神経炎症及び神経変性を管理するための方法及び組成物

Country Status (3)

Country Link
US (1) US11324747B2 (enExample)
JP (1) JP2019521116A (enExample)
WO (1) WO2017212420A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041245C (en) 2016-11-25 2022-12-06 Shine Biopharma Inc. Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US20190388407A1 (en) 2017-02-12 2019-12-26 Aiviva Biopharma, Inc. Multikinase inhibitors of vegf and tfg beta and uses thereof
CN110769828A (zh) * 2017-05-12 2020-02-07 香港科技大学 作为epha4抑制剂的杂环化合物
KR102106821B1 (ko) 2018-04-27 2020-05-06 재단법인대구경북과학기술원 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
WO2019209065A1 (ko) * 2018-04-27 2019-10-31 재단법인대구경북과학기술원 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
WO2020036934A1 (en) * 2018-08-13 2020-02-20 The Regents Of The University Of Michigan Methods for treating amyotrophic lateral sclerosis
EP3836927A4 (en) 2018-08-15 2022-05-11 AiViva Biopharma, Inc. MULTIKINASE INHIBITORS OF VEGF AND TGF-BETA AND THEIR USES
CN111374977B (zh) * 2018-12-27 2022-03-18 浙江大学 阿西替尼及其类似物在制备血脑屏障渗透性调控剂中的应用
CN109893502B (zh) * 2019-03-27 2022-12-02 南京格亚医药科技有限公司 一种枸橼酸托法替布组合物及其制备方法
CN113197898A (zh) * 2021-06-03 2021-08-03 广州医科大学 卡博替尼在制备防治nlrp3炎症小体相关疾病的药物中的应用
CN113230255A (zh) * 2021-06-03 2021-08-10 广州医科大学 阿帕替尼在制备防治nlrp3炎症小体相关疾病的药物中的应用
CN115804773A (zh) * 2022-08-15 2023-03-17 苏州大学 帕唑帕尼在制备神经炎症抑制剂中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263578B2 (en) * 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
CA2911040C (en) * 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AGEING RESEARCH REVIEWS, vol. 15, JPN6021023140, 2014, pages 116 - 145, ISSN: 0004695778 *
BRAIN AND BEHAVIOR, vol. 4, no. 2, JPN6021023139, 2014, pages 108 - 122, ISSN: 0004695777 *
DEMENT GERIATR COGN DISORD, vol. 35, JPN6021023137, 2013, pages 1 - 22, ISSN: 0004695776 *

Also Published As

Publication number Publication date
US11324747B2 (en) 2022-05-10
US20190255054A1 (en) 2019-08-22
WO2017212420A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
US11324747B2 (en) Methods and compositions for managing neuroinflammation and neurodegeneration
Khasnavis et al. Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson’s disease
Jung et al. Suppression of lipopolysaccharide-induced neuroinflammation by morin via MAPK, PI3K/Akt, and PKA/HO-1 signaling pathway modulation
JP2023107934A (ja) ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
KR101918669B1 (ko) 신경 장애 치료용 신규 조성물
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
WO2024258363A1 (en) Use of gsk-3 activatior to modulate proteasome activity to prevent ageing associated conditions and diseases
BRPI0914902B1 (pt) Composição farmacêutica para uso no tratamento de mal de parkinson
US20200325148A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
WO2014014828A1 (en) Nicotinamide riboside to treat hearing loss
JP2022160605A (ja) ｓＧＣ刺激薬による中枢神経系疾患の治療
WO2010015260A2 (en) Administration by infusion for the treatment of ischemic effects
JP5952890B2 (ja) 膵臓癌を治療するための医薬製剤
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
WO2020132378A2 (en) Compositions and methods of treatment for neurological disorders comprising depression
Zhao et al. α-Lipoic acid alleviated fluoride-induced hepatocyte injury via inhibiting ferroptosis
TW202108585A (zh) 用於治療地中海型貧血之pde9抑制劑
Parent et al. Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular γ-aminobutyric acid levels in the striatum
CA2631740A1 (en) Methods and compositions for the treatment of disease
JP6975165B2 (ja) 脳細胞傷害の処置における使用のための２−イミノビオチン
JP2020536048A (ja) 発毛を調節するための組成物及び方法
Zimmer et al. In vivo screening of S100B inhibitors for melanoma therapy
Pang et al. Synergistic protective effect of FTY720 and vitamin E against simulated cerebral ischemia in vitro
KR102645209B1 (ko) 항스트레스, 항불안, 및 항우울 활성을 갖는 작용제 및 이를 기반으로 하는 조성물
TW202404571A (zh) 藥物組成物及化療劑用於製備治療癌症之藥物的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201